论文部分内容阅读
目的依折麦布干预对2型糖尿病模型db/db小鼠体内脂肪因子和胰岛素抵抗(insulin resistance,IR)的影响。方法将40只8周龄雄性db/db小鼠随机均分为依折麦布组和db/db对照组,分别给予依折麦布10 mg/(kg·d)和安慰剂灌胃。另选择20只同周龄非糖尿病(db/m小鼠)作为对照组(db/m组)。3组小鼠分别于治疗前和治疗后6周测定低密度脂蛋白(lowdensity lipoprotein,LDL)、甘油三酯(triglyceride,TC)、空腹血糖(fasting blood glucose,FBG)、空腹胰岛素(fasting serum insulin,FSI),并计算胰岛素敏感指数(insulin sensitivity index,ISI),脂联素(adiponectin,APN),趋化素水平。结果给药6周后,db/db组血清趋化素明显升高,APN水平明显下降;而依折麦布组小鼠趋化素明显下降,APN水平明显升高,治疗前后比较差异均具有统计学意义(P<0.05)。给药6周后趋化素、APN水平组间比较差异均具有统计学意义(P<0.01)。依折麦布与△趋化素呈负相关,与△APN呈正相关;△趋化素与△FBG、△FSI、△ISI呈正相关;△APN与△FBG、△FSI、△ISI呈负相关。结论依折麦布可以明显调节db/db小鼠体内趋化素和APN水平,促进胰岛素分泌,改善胰岛素抵抗(insulin resistance,IR)程度。
OBJECTIVE: To investigate the effects of emamectin (ET) on the adipokines and insulin resistance (IR) in type 2 diabetic db / db mice. Methods Forty 8-week-old male db / db mice were randomly divided into ezetimibe and db / db control groups, and were given orally ezetimibe 10 mg / (kg · d) and placebo orally. Another 20 weeks of non-diabetic age (db / m mice) as a control group (db / m group). Three groups of mice were used to measure the levels of low density lipoprotein (LDL), triglyceride (TC), fasting blood glucose (FBG), fasting serum insulin (before and 6 weeks after treatment) , FSI), and insulin sensitivity index (ISI), adiponectin (APN) and chemotactic factor levels were calculated. Results After 6 weeks of administration, the concentrations of chemokines in db / db group were significantly increased and APN levels were significantly decreased. In the ezetimibe group, the chemokines were significantly decreased and APN levels were significantly increased, with significant differences before and after treatment Statistical significance (P <0.05). After 6 weeks of administration, there was significant difference between chemotactic and APN levels (P <0.01). Ezetimibe was negatively correlated with △ Chemokine and positively correlated with △ APN; △ Chemokine was positively correlated with △ FBG, △ FSI and △ ISI; △ APN was negatively correlated with △ FBG, △ FSI and △ ISI. Conclusion Ezetimibe significantly modulates the levels of chemokines and APN in db / db mice, promotes insulin secretion and improves insulin resistance (IR).